ImmuneOnco Biopharmaceuticals Reports No Change in Share Capital for May 2026

Bulletin Express

Jun 03

On 3 June 2026, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. filed its Monthly Return to the Hong Kong Stock Exchange, covering the period ended 31 May 2026.

Registered share capital remained at RMB 431.51 million, split between 420.48 million H shares and 11.03 million unlisted domestic shares, both with a par value of RMB 1.00.

Issued share capital was unchanged at 420.48 million H shares and 11.03 million unlisted shares, with no treasury shares reported.

The company confirmed compliance with the Main Board’s minimum public-float requirement, maintaining at least 25% of H-share free float.

No movements were recorded under share options, warrants, convertible instruments, or other share issuance arrangements during the month.

The filing was signed by Executive Director and Joint Company Secretary Guan Mei.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1142865531"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1142865531\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1142865531?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-03 16:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1142865531","market":"us","top_or_hot":-1,"title":"ImmuneOnco Biopharmaceuticals Reports No Change in Share Capital for May 2026","media":"Bulletin Express","content":"<p>On 3 June 2026, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. filed its Monthly Return to the Hong Kong Stock Exchange, covering the period ended 31 May 2026.</p>\n<p>Registered share capital remained at RMB 431.51 million, split between 420.48 million H shares and 11.03 million unlisted domestic shares, both with a par value of RMB 1.00.</p>\n<p>Issued share capital was unchanged at 420.48 million H shares and 11.03 million unlisted shares, with no treasury shares reported.</p>\n<p>The company confirmed compliance with the Main Board’s minimum public-float requirement, maintaining at least 25% of H-share free float.</p>\n<p>No movements were recorded under share options, warrants, convertible instruments, or other share issuance arrangements during the month.</p>\n<p>The filing was signed by Executive Director and Joint Company Secretary Guan Mei.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImmuneOnco Biopharmaceuticals Reports No Change in Share Capital for May 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmuneOnco Biopharmaceuticals Reports No Change in Share Capital for May 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-03 16:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On 3 June 2026, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. filed its Monthly Return to the Hong Kong Stock Exchange, covering the period ended 31 May 2026.</p>\n<p>Registered share capital remained at RMB 431.51 million, split between 420.48 million H shares and 11.03 million unlisted domestic shares, both with a par value of RMB 1.00.</p>\n<p>Issued share capital was unchanged at 420.48 million H shares and 11.03 million unlisted shares, with no treasury shares reported.</p>\n<p>The company confirmed compliance with the Main Board’s minimum public-float requirement, maintaining at least 25% of H-share free float.</p>\n<p>No movements were recorded under share options, warrants, convertible instruments, or other share issuance arrangements during the month.</p>\n<p>The filing was signed by Executive Director and Joint Company Secretary Guan Mei.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01541","symbol_name":"宜明昂科-B","start_time":0,"source_url":"","article_id":"1142865531","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1142865531","pubTimestamp":1780476251,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"On 3 June 2026, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. filed its Monthly Return to the Hong Kong Stock Exchange, covering the period ended 31 May 2026. Registered share capital remained at RMB...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01541":"宜明昂科-B"},"translate_title":"ImmuneOnco Biopharmaceuticals报告2026年5月股本没有变化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01541":1},"content_text":"On 3 June 2026, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. filed its Monthly Return to the Hong Kong Stock Exchange, covering the period ended 31 May 2026.\nRegistered share capital remained at RMB 431.51 million, split between 420.48 million H shares and 11.03 million unlisted domestic shares, both with a par value of RMB 1.00.\nIssued share capital was unchanged at 420.48 million H shares and 11.03 million unlisted shares, with no treasury shares reported.\nThe company confirmed compliance with the Main Board’s minimum public-float requirement, maintaining at least 25% of H-share free float.\nNo movements were recorded under share options, warrants, convertible instruments, or other share issuance arrangements during the month.\nThe filing was signed by Executive Director and Joint Company Secretary Guan Mei.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}